Voyager Therapeutics (VYGR) Equity Ratio (2014 - 2026)

Voyager Therapeutics has disclosed Equity Ratio across 13 years of filings, most recently posting 0.79 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.79, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.79 (up 2.57% YoY), and the FY2025 annual result was 0.78, up 1.91% from the prior year.
• Equity Ratio came in at 0.79 for Q1 2026 at Voyager Therapeutics, up from 0.78 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.79 in Q1 2026 to a low of 0.32 in Q2 2022.
• The 5-year median for Equity Ratio is 0.73 (2024), against an average of 0.64.
• Across the five-year window, Equity Ratio slumped 40.89% in 2022 and jumped 98.1% in 2023, its largest moves.
• Voyager Therapeutics' Equity Ratio stood at 0.37 in 2022, then soared by 81.64% to 0.67 in 2023, then rose by 13.37% to 0.76 in 2024, then climbed by 1.91% to 0.78 in 2025, then grew by 1.88% to 0.79 in 2026.
• The last three Equity Ratio figures came in at 0.79 (Q1 2026), 0.78 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.